Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00036231
Status:
TERMINATED
Last Update Posted:
2005-11-21
First Post:
2002-05-08
Brief Title:
Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
Sponsor:
Repligen Corporation
Organization:
Repligen Corporation
Study Overview
Official Title:
A Phase III Randomized Double-Blind Placebo-Controlled Multiple Dose Study to Assess the Efficacy Safety and Tolerability of RG1068 Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
Status:
TERMINATED
Status Verified Date:
2005-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to determine the effect of multiple doses of secretin on autism
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None